Antibody Drug Target Atlas in Oncology

Where to Commercialize in a Crowded Market Place?

Product Code BSK00012
Publication Date March 2010
Publisher Bioseeker
Product Type Report
Pages 1289
ISBN Number not applicable
Change currency
PDF £2,035.00 €2,451 $3,218 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Antibody Drug Target Atlas in Oncology

Where to Commercialize in a Crowded Market Place?

The antibody market represents the fastest-growing segment within the pharmaceutical industry. As such it has become a complex and crowded market place. This is particularly true for the cancer market. When navigating in the competitive landscape of antibody therapeutics in oncology one has to consider available options for your own drug pipeline as well as the position of others.

This report comprises defined and up to date development strategies for 441 antibody drugs (993 projects) within the portfolio of 168 investigators, from Ceased to Marketed. The report extensively analyses 225 identified targets of antibody drugs, organized into 234 drug target profiles, and assesses them in 69 different cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies' portfolio planning and new product planning by:

  • Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
  • Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
  • Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
  • Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report will also be an important part of creating and implementing a market development plan for any antibody drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized.

Contents

  • 1 Executive Summary
  • 2 About Cancer Highlights
  • 3 Methodologies
  • 4 Table of Contents
    • 4.1 List of Figures
    • 4.2 List of Tables
  • 5 Introduction
    • 5.1 Background to the Antibody Therapeutic Market
    • 5.2 The Scope of this Report
    • 5.3 Definitions
    • 5.4 Abbreviations
  • 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment
    • 6.1 Drug Repositioning in Oncology
    • 6.2 Introduction to Antibody Therapeutic Targets in Oncology
      • 6.2.1 Antigen Binding Targets
      • 6.2.2 Auxiliary Transport Protein Activity Targets
      • 6.2.3 B Cell Receptor Activity Targets
      • 6.2.4 Carboxypeptidase Activity Targets
      • 6.2.5 Catalytic Activity Targets
      • 6.2.6 Cell Adhesion Molecule Activity Targets
      • 6.2.7 Cell Adhesion Molecule Activity Targets
      • 6.2.8 Chaperone Activity Targets
      • 6.2.9 Chemokine Activity Targets
      • 6.2.10 Cofactor Binding Targets
      • 6.2.11 Complement Activity Targets
      • 6.2.12 Cysteine-Type Peptidase Activity Targets
      • 6.2.13 Cytokine Activity Targets
      • 6.2.14 Defense/immunity Protein Activity Targets
      • 6.2.15 DNA Topoisomerase Activity Targets
      • 6.2.16 Extracellular Ligand-Gated Ion Channel Activity Targets
      • 6.2.17 Extracellular Matrix Structural Constituent Targets
      • 6.2.18 G-protein Coupled Receptor Activity Targets
      • 6.2.19 Growth Factor Activity Targets
      • 6.2.20 Hormone Activity Targets
      • 6.2.21 Hydrolase Activity Targets
      • 6.2.22 Intracellular Ligand-Gated Ion Channel Activity Targets
      • 6.2.23 Isomerase Activity Targets
      • 6.2.24 Kinase Binding Targets
      • 6.2.25 Lipid Kinase Activity Targets
      • 6.2.26 Metallopeptidase Activity Targets
      • 6.2.27 MHC Class I Receptor Activity Targets
      • 6.2.28 Molecular Function Unknown Targets
      • 6.2.29 Oxidoreductase Activity Targets
      • 6.2.30 Peptidase Activity Targets
      • 6.2.31 Peptide Hormone Targets
      • 6.2.32 Protease Inhibitor Activity Targets
      • 6.2.33 Protease Inhibitor Activity Targets
      • 6.2.34 Protein Binding Targets
      • 6.2.35 Protein Serine/Threonine Kinase Activity Targets
      • 6.2.36 Receptor Activity Targets
      • 6.2.37 Receptor Binding Targets
      • 6.2.38 Receptor Signaling Complex Scaffold Activity Targets
      • 6.2.39 RNA-directed DNA Polymerase Activity Targets
      • 6.2.40 Serine-type Peptidase Activity Targets
      • 6.2.41 Structural Constituent of Cytoskeleton Targets
      • 6.2.42 T cell Receptor Activity Targets
      • 6.2.43 Transcription Factor Activity Targets
      • 6.2.44 Transcription Regulator Activity Targets
      • 6.2.45 Transmembrane Receptor Activity Targets
      • 6.2.46 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
      • 6.2.47 Transporter Activity Targets
      • 6.2.48 Unclassified Targets
    • 6.3 The Cancer Genome Project and Antibody Therapeutic Targets in Oncology
      • 6.3.1 Antibody Therapeutic Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
    • 6.4 Structure-based Drug Design in Antibody Therapeutics is Stimulated by Available Structure Data on Biological Targets
    • 6.5 Target-Target Interactions among Identified Antibody Therapeutics Targets in Oncology
    • 6.6 The Drug-Target Interactome
    • 6.7 Protein Expression Levels of Identified Antibody Therapeutic Targets in Oncology
    • 6.8 Pathway Analysis of Cancer Antibody Therapeutic Targets
  • 7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Antibody Therapeutic Pipeline?
    • 7.1 Terminated Drug Target Profiles of Cancer Antibody Drugs
    • 7.2 Pre-Registration to being Marketed: New and Unique Drug Target Profiles of Antibody Therapeutics in Oncology
    • 7.3 Phase III Clinical Development: New and Unique Drug Target Profiles of Antibody Therapeutics in Oncology
    • 7.4 Phase II Clinical Development: New and Unique Drug Target Profiles of Antibody Therapeutics in Oncology
    • 7.5 Phase I Clinical Development: New and Unique Drug Target Profiles of Antibody Therapeutics in Oncology
    • 7.6 Preclinical Development: New and Unique Drug Target Profiles of Antibody Therapeutics in Oncology
    • 7.7 Development Profiles of All Antibody Drugs in Oncology
    • 7.8 The Competition Through Close Mechanistic Approximation of Antibody Cancer Therapeutics
  • 8 Selecting Cancer Indications for Antibody Therapeutics
    • 8.1 Acute Lymphocytic Leukemia
    • 8.2 Acute Myelogenous Leukemia
    • 8.3 Basal Cell Cancer
    • 8.4 B-cell Lymphoma
    • 8.5 Biliary Cancer
    • 8.6 Bladder Cancer
    • 8.7 Bone Cancer
    • 8.8 Brain Cancer
    • 8.9 Breast Cancer
    • 8.10 Cancer (general)
    • 8.11 Cancer Diagnosis
    • 8.12 Cancer Fatigue
    • 8.13 Carcinoid Tumor
    • 8.14 Cervical Cancer
    • 8.15 Chemotherapy-induced Anemia
    • 8.16 Chemotherapy-induced Bone Marrow Injury (general)
    • 8.17 Chemotherapy-induced Injury (general)
    • 8.18 Chemotherapy-induced Thrombocytopenia
    • 8.19 Chronic Lymphocytic Leukemia
    • 8.20 Chronic Myelogenous Leukemia
    • 8.21 CNS Cancer
    • 8.22 Colorectal Cancer
    • 8.23 Endometrial Cancer
    • 8.24 Ewing's Sarcoma
    • 8.25 Fallopian Tube Cancer
    • 8.26 Gastrointestinal Cancer (general)
    • 8.27 Gastrointestinal Stomach Cancer
    • 8.28 Gastrointestinal Stromal Cancer
    • 8.29 Genitourinary Cancer
    • 8.30 Hairy Cell Leukemia
    • 8.31 Head and Neck Cancer
    • 8.32 Hematological Cancer (general)
    • 8.33 Hodgkin's Lymphoma
    • 8.34 Leiomyo Sarcoma
    • 8.35 Leukemia (general)
    • 8.36 Liver Cancer
    • 8.37 Lung Cancer (general)
    • 8.38 Lymphoma (general)
    • 8.39 Melanoma
    • 8.40 Merkel Cell Carcinoma
    • 8.41 Mesothelioma
    • 8.42 Myelodysplastic Syndrome
    • 8.43 Myeloma
    • 8.44 Nasopharyngeal Cancer
    • 8.45 Neuroblastoma
    • 8.46 Neuroectodermal Sarcoma
    • 8.47 Neuroendocrine Cancer (general)
    • 8.48 non-Hodgkin's Lymphoma
    • 8.49 Non-Small Cell Lung Cancer
    • 8.50 Oesophageal Cancer
    • 8.51 Osteo Sarcoma
    • 8.52 Ovarian Cancer
    • 8.53 Pancreatic Cancer
    • 8.54 Peritoneal Cancer
    • 8.55 Prostate Cancer
    • 8.56 Renal Cancer
    • 8.57 Rhabdomyo Sarcoma
    • 8.58 Sarcoma (general)
    • 8.59 Skin Cancer (general)
    • 8.60 Small Cell Lung Cancer
    • 8.61 Soft Tissue Sarcoma
    • 8.62 Solid Tumor
    • 8.63 Squamous Cell Cancer
    • 8.64 Synovial Sarcoma
    • 8.65 T-cell Lymphoma
    • 8.66 Testicular Cancer
    • 8.67 Thyroid Cancer
    • 8.68 Unspecified Cancer Indication
    • 8.69 Vaccine Adjunct
  • 9 Portfolio Planning: Competitive Benchmarking of Antibody Cancer Therapeutic Pipeline by Investigator
    • 9.1 A&G Pharmaceutical
    • 9.2 Abiogen
    • 9.3 Ablynx
    • 9.4 AC Immune
    • 9.5 Access
    • 9.6 Actinium Pharmaceuticals
    • 9.7 Active Biotech
    • 9.8 Adherex
    • 9.9 Affibody
    • 9.10 Affimed Therapeutics
    • 9.11 Affitech
    • 9.12 AGY Therapeutics
    • 9.13 Aida Pharmaceuticals
    • 9.14 Alder Biopharmaceuticals
    • 9.15 Alethia Biotherapeutics
    • 9.16 Alexion
    • 9.17 Algeta
    • 9.18 Amgen
    • 9.19 Antisoma
    • 9.20 Aphios
    • 9.21 Arana Therapeutics
    • 9.22 Arca biopharma
    • 9.23 Astellas
    • 9.24 AstraZeneca
    • 9.25 Attenuon
    • 9.26 AVEO
    • 9.27 Bayer
    • 9.28 Berkeley Lab
    • 9.29 Biocon
    • 9.30 Biogen Idec
    • 9.31 BioInvent
    • 9.32 Biolex
    • 9.33 BioLineRx
    • 9.34 Biosceptre
    • 9.35 Biotecnol
    • 9.36 Boehringer Ingelheim
    • 9.37 Bristol-Myers Squibb
    • 9.38 BTG
    • 9.39 Cancer Innovations
    • 9.40 Cancer Research Technology
    • 9.41 Celldex Therapeutics
    • 9.42 Celtic Pharma
    • 9.43 Center of Molecular Immunology
    • 9.44 CG Therapeutics
    • 9.45 Circadian Technologies
    • 9.46 CuraGen
    • 9.47 CureTech
    • 9.48 Curis
    • 9.49 CytImmune Sciences
    • 9.50 Daiichi Sankyo
    • 9.51 Dendreon
    • 9.52 Dompe
    • 9.53 Dyax
    • 9.54 Eisai
    • 9.55 Elan
    • 9.56 Eli Lilly
    • 9.57 Epitomics
    • 9.58 EUSA Pharma
    • 9.59 Facet Biotech
    • 9.60 Faron Pharmaceuticals
    • 9.61 Favrille
    • 9.62 FibroGen
    • 9.63 Five Prime Therapeutics
    • 9.64 Fusion Antibodies
    • 9.65 Galaxy Biotech
    • 9.66 GammaCan
    • 9.67 Ganymed Pharmaceuticals
    • 9.68 Gene Techno Science
    • 9.69 Genentech
    • 9.70 Genmab
    • 9.71 GenPat77
    • 9.72 Genzyme
    • 9.73 GlaxoSmithKline
    • 9.74 Gliknik
    • 9.75 Glycotope
    • 9.76 Green Cross
    • 9.77 GTC Biotherapeutics
    • 9.78 Hoffmann-La Roche
    • 9.79 Human Genome Sciences
    • 9.80 IDM Pharma
    • 9.81 ImClone Systems
    • 9.82 ImmunoCellular Therapeutics
    • 9.83 ImmunoGen
    • 9.84 Immunomedics
    • 9.85 Innate Pharma
    • 9.86 InNexus Biotechnology
    • 9.87 Intracel
    • 9.88 ISA Pharmaceuticals
    • 9.89 ISU ABXIS
    • 9.90 Johnson & Johnson
    • 9.91 Kaketsuken
    • 9.92 KaloBios
    • 9.93 Kirin Pharma
    • 9.94 Kissei
    • 9.95 Kyowa Hakko Kirin
    • 9.96 LFB Biotechnologies
    • 9.97 MacroGenics
    • 9.98 MAT Biopharma
    • 9.99 Medarex
    • 9.100 MediGene
    • 9.101 MedImmune
    • 9.102 Menarini
    • 9.103 Merck & Co 1002
    • 9.104 Merck KGaA 1008
    • 9.105 Merrimack 1015
    • 9.106 Micromet 1018
    • 9.107 MorphoSys 1030
    • 9.108 Neovacs 1033
    • 9.109 Neuren 1037
    • 9.110 NKT Therapeutics 1040
    • 9.111 Non-industrial Sources 1043
    • 9.112 Northwest Biotherapeutics 1048
    • 9.113 Novartis 1051
    • 9.114 OncoMed 1059
    • 9.115 Onyvax 1062
    • 9.116 Oxford BioMedica 1065
    • 9.117 Paladin Labs 1068
    • 9.118 Panacea 1073
    • 9.119 PanGenetics 1077
    • 9.120 Patrys 1081
    • 9.121 Pepscan Therapeutics 1085
    • 9.122 Peregrine Pharmaceuticals 1090
    • 9.123 Pfizer 1095
    • 9.124 Philogen 1105
    • 9.125 Pierre Fabre 1108
    • 9.126 Prima Biomed 1114
    • 9.127 ProCell Therapeutics 1117
    • 9.128 Prochon Biotech 1120
    • 9.129 Progenics Pharmaceuticals 1123
    • 9.130 Protherics 1126
    • 9.131 Ramot 1129
    • 9.132 Recepta biopharma 1132
    • 9.133 Receptor BioLogix 1135
    • 9.134 Regeneron 1139
    • 9.135 Sanofi-Aventis 1144
    • 9.136 Scancell 1147
    • 9.137 Seattle Genetics 1150
    • 9.138 Sirtex Medical 1158
    • 9.139 Sunol Molecular 1162
    • 9.140 SuppreMol 1165
    • 9.141 Switch Pharma 1168
    • 9.142 Symphogen 1171
    • 9.143 SynerGene Therapeutics 1176
    • 9.144 Takeda 1179
    • 9.145 Targa Therapeutics 1182
    • 9.146 TeGenero 1187
    • 9.147 Teva 1190
    • 9.148 Therapure Biopharma 1193
    • 9.149 ThromboGenics 1196
    • 9.150 Titan Pharmaceuticals 1199
    • 9.151 Tolerx 1204
    • 9.152 Tracon Pharmaceuticals 1207
    • 9.153 Trillium Therapeutics 1210
    • 9.154 Trion Pharma 1213
    • 9.155 Trubion 1218
    • 9.156 UCB 1221
    • 9.157 United Therapeutics 1225
    • 9.158 Vaccinex 1228
    • 9.159 VasGene Therapeutics 1233
    • 9.160 Viragen 1236
    • 9.161 Viventia Biotech 1239
    • 9.162 Wilex 1242
    • 9.163 Xencor 1245
    • 9.164 Xerion 1257
    • 9.165 Xoma 1262
    • 9.166 Y's Therapeutics 1266
  • 10 Disclaimer 1269
  • 11 Drug Index 1270
  • 12 Company Index 1282
  • List of Figures
    • Figure 1: Visualization of Target-Target Interactions among Antibody Drug Targets in Oncology
    • Figure 2: The Drug-Protein Interactome of Antibody Drugs Large Clusters
    • Figure 3: The Drug-Protein Interactome of Antibody Drugs Small Clusters
    • Figure 4: Head-to-Head Targeting Interactome of Antibody Drugs Large Clusters
    • Figure 5: Head-to-Head Targeting Interactome of Antibody Drugs Small Clusters
  • List of Tables
    • Table 1: Head to Head Competition among Apoptopic Drugs in Oncology
    • Table 2: Overall Breakdown of the Included Antibody Pipeline by Cancer Indication and Stage of Development
    • Table 3: Overview of Drug Target Profile Themes
    • Table 4: Terminally Ceased Therapeutic Antibody Targets in Oncology
    • Table 5: Drug Targets of Antibody Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
    • Table 6: Identity of Antibody Drug Targets with Available Biological Structures
    • Table 7: Number of Target-Target Interactions among Antibody Drug Targets in Oncology
    • Table 8: Antibody Drug Targets with Available Protein Expression Profiles
    • Table 9: Pathway Summary
    • Table 10: Drug Targets without any Identified Assigned Pathways
    • Table 11: Pathway Profiles According to BioCarta of Antibody Drug Targets in Oncology
    • Table 12: Pathway Profiles According to KEGG of Antibody Drug Targets in Oncology
    • Table 13: Pathway Profiles According to NetPath of Antibody Drug Targets in Oncology
    • Table 14: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness
    • Table 15: Top Competitive Antibody Target Profiles in Oncology
    • Table 16: Terminated Drug Target Strategies of Antibody Drugs in Oncology
    • Table 17 New and Unique Antibody Target Strategies in Cancer Currently in Pre-Registration to Marketed
    • Table 18: The Competition Through Close Mechanistic Approximation Between Pre-registration to Marketed Antibody Drugs in Oncology
    • Table 19: New and Unique Antibody Target Strategies in Cancer Currently in Phase III Clinical Development
    • Table 20: The Competition Through Close Mechanistic Approximation Between Phase III Antibody Drugs in Oncology
    • Table 21: New and Unique Antibody Target Strategies in Cancer Currently in Phase II Clinical Development
    • Table 22: The Competition Through Close Mechanistic Approximation Between Phase II Antibody Drugs in Oncology
    • Table 23 New and Unique Antibody Target Strategies in Cancer Currently in Phase I Clinical Development
    • Table 24: The Competition Through Close Mechanistic Approximation Between Phase I Antibody Drugs in Oncology
    • Table 25: New and Unique Antibody Target Strategies in Oncology Currently in Preclinical Development
    • Table 26: The Competition Through Close Mechanistic Approximation Between Preclinical Antibody Drugs in Oncology
    • Table 27: The Progression, Maturity and Competitive Comparison of Antibody Drug Target Profiles in Cancer Drug Development
    • Table 28: The Competition Through Close Mechanistic Approximation Among All Antibody Drugs in Oncology
    • Table 29: Competitive Summary of Antibody Drugs by Cancer Indication
    • Table 30: Drug Target Profiles of Antibody Drugs for the Treatment of Acute Lymphocytic Leukemia
    • Table 31: The Competition through Close Mechanistic Approximation between Acute Lymphocytic Leukemia Drugs
    • Table 32: Drug Target Profiles of Antibody Drugs for the Treatment of Acute Myelogenous Leukemia
    • Table 33: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs
    • Table 34: Drug Target Profiles of Antibody Drugs for the Treatment of Basal Cell Cancer
    • Table 35: Drug Target Profiles of Antibody Drugs for the Treatment of B-cell Lymphoma
    • Table 36: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs
    • Table 37: Drug Target Profiles of Antibody Drugs for the Treatment of Biliary Cancer
    • Table 38: The Competition through Close Mechanistic Approximation between Biliary Cancer Drugs
    • Table 39: Drug Target Profiles of Antibody Drugs for the Treatment of Bladder Cancer
    • Table 40: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs
    • Table 41: Drug Target Profiles of Antibody Drugs for the Treatment of Bone Cancer
    • Table 42: Drug Target Profiles of Antibody Drugs for the Treatment of Brain Cancer
    • Table 43: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs
    • Table 44: Drug Target Profiles of Antibody Drugs for the Treatment of Breast Cancer
    • Table 45: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs
    • Table 46: Drug Target Profiles of Antibody Drugs for the Treatment of Cancer (general)
    • Table 47: The Competition through Close Mechanistic Approximation between Cancer (general)
    • Table 48: Drug Target Profiles of Antibody Drugs for Cancer Diagnosis
    • Table 49: The Competition through Close Mechanistic Approximation between Cancer Diagnosis Drugs
    • Table 50: Drug Target Profiles of Antibody Drugs for the Treatment of Cancer Fatigue
    • Table 51: Drug Target Profiles of Antibody Drugs for the Treatment of Carcinoid Tumor
    • Table 52: Drug Target Profiles of Antibody Drugs for the Treatment of Cervical Cancer
    • Table 53: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs
    • Table 54: Drug Target Profiles of Antibody Drugs for the Treatment of Chemotherapy-induced Anemia
    • Table 55: Drug Target Profiles of Antibody Drugs for the Treatment of Chemotherapy-induced Bone Marrow Injury (general)
    • Table 56: Drug Target Profiles of Antibody Drugs for the Treatment of Chemotherapy-induced Injury (general)
    • Table 57: Drug Target Profiles of Antibody Drugs for the Treatment of Chemotherapy-induced Thrombocytopenia
    • Table 58: Drug Target Profiles of Antibody Drugs for the Treatment of Chronic Lymphocytic Leukemia
    • Table 59: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs
    • Table 60: Drug Target Profiles of Antibody Drugs for the Treatment of Chronic Myelogenous Leukemia
    • Table 61: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia
    • Table 62: Drug Target Profiles of Antibody Drugs for the Treatment of CNS Cancer
    • Table 63: Drug Target Profiles of Antibody Drugs for the Treatment of Colorectal Cancer
    • Table 64: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs
    • Table 65: Drug Target Profiles of Antibody Drugs for the Treatment of Endometrial Cancer
    • Table 66: Drug Target Profiles of Antibody Drugs for the Treatment of Ewing's Sarcoma
    • Table 67: The Competition through Close Mechanistic Approximation between Ewing's Sarcoma Drugs
    • Table 68: Drug Target Profiles of Antibody Drugs for the Treatment of Fallopian Tube Cancer
    • Table 69: Drug Target Profiles of Antibody Drugs for the Treatment of Gastrointestinal Cancer (general)
    • Table 70: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs
    • Table 71: Drug Target Profiles of Antibody Drugs for the Treatment of Gastrointestinal Stomach Cancer
    • Table 72: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs
    • Table 73: Drug Target Profiles of Antibody Drugs for the Treatment of Gastrointestinal Stromal Cancer
    • Table 74: Drug Target Profiles of Antibody Drugs for the Treatment of Genitourinary Cancer
    • Table 75: The Competition through Close Mechanistic Approximation between Genitourinary Cancer Drugs
    • Table 76: Drug Target Profiles of Antibody Drugs for the Treatment of Hairy Cell Leukemia
    • Table 77: Drug Target Profiles of Antibody Drugs for the Treatment of Head and Neck Cancer
    • Table 78: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs
    • Table 79: Drug Target Profiles of Antibody Drugs for the Treatment of Hematological Cancer (general)
    • Table 80: Drug Target Profiles of Antibody Drugs for the Treatment of Hodgkin's Lymphoma
    • Table 81: The Competition through Close Mechanistic Approximation between Hodgkin's Lymphoma Drugs
    • Table 82: Drug Target Profiles of Antibody Drugs for the Treatment of Leiomyo Sarcoma
    • Table 83: Drug Target Profiles of Antibody Drugs for the Treatment of Leukemia (general)
    • Table 84: Drug Target Profiles of Antibody Drugs for the Treatment of Liver Cancer
    • Table 85: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs
    • Table 86: Drug Target Profiles of Antibody Drugs for the Treatment of Lung Cancer (general)
    • Table 87: The Competition through Close Mechanistic Approximation between Lung Cancer (general)Drugs
    • Table 88: Drug Target Profiles of Antibody Drugs for the Treatment of Lymphoma (general)
    • Table 89: Drug Target Profiles of Antibody Drugs for the Treatment of Melanoma
    • Table 90: The Competition through Close Mechanistic Approximation between Melanoma Drugs
    • Table 91: Drug Target Profiles of Antibody Drugs for the Treatment of Merkel Cell Carcinoma
    • Table 92: Drug Target Profiles of Antibody Drugs for the Treatment of Mesothelioma
    • Table 93: The Competition through Close Mechanistic Approximation between Mesothelioma Drugs
    • Table 94: Drug Target Profiles of Antibody Drugs for the Treatment of Myelodysplastic Syndrome
    • Table 95: Drug Target Profiles of Antibody Drugs for the Treatment of Myeloma
    • Table 96: The Competition through Close Mechanistic Approximation between Myeloma Drugs
    • Table 97: Drug Target Profiles of Antibody Drugs for the Treatment of Nasopharyngeal Cancer
    • Table 98: Drug Target Profiles of Antibody Drugs for the Treatment of Neuroblastoma
    • Table 99: Drug Target Profiles of Antibody Drugs for the Treatment of Neuroectodermal Sarcoma
    • Table 100: Drug Target Profiles of Antibody Drugs for the Treatment of Neuroendocrine Cancer (general)
    • Table 101: Drug Target Profiles of Antibody Drugs for the Treatment of non-Hodgkin's Lymphoma
    • Table 102: The Competition through Close Mechanistic Approximation between non-Hodgkin's Lymphoma Drugs
    • Table 103: Drug Target Profiles of Antibody Drugs for the Treatment of Non-Small Cell Lung Cancer
    • Table 104: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs
    • Table 105: Drug Target Profiles of Antibody Drugs for the Treatment of Oesophageal Cancer
    • Table 106: The Competition through Close Mechanistic Approximation between Oesophageal Cancer
    • Table 107: Drug Target Profiles of Antibody Drugs for the Treatment of Osteo Sarcoma
    • Table 108: The Competition through Close Mechanistic Approximation between Osteo Sarcoma Drugs
    • Table 109: Drug Target Profiles of Antibody Drugs for the Treatment of Ovarian Cancer
    • Table 110: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs
    • Table 111: Drug Target Profiles of Antibody Drugs for the Treatment of Pancreatic Cancer
    • Table 112: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs
    • Table 113: Drug Target Profiles of Antibody Drugs for the Treatment of Peritoneal Cancer
    • Table 114: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs
    • Table 115: Drug Target Profiles of Antibody Drugs for the Treatment of Prostate Cancer
    • Table 116: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs
    • Table 117: Drug Target Profiles of Antibody Drugs for the Treatment of Renal Cancer
    • Table 118: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs
    • Table 119: Drug Target Profiles of Antibody Drugs for the Treatment of Rhabdomyo Sarcoma
    • Table 120: The Competition through Close Mechanistic Approximation between rhabdomyo sarcoma Drugs
    • Table 121: Drug Target Profiles of Antibody Drugs for the Treatment of Sarcoma (general)
    • Table 122: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs
    • Table 123: Drug Target Profiles of Antibody Drugs for the Treatment of Skin Cancer (general)
    • Table 124: Drug Target Profiles of Antibody Drugs for the Treatment of Small Cell Lung Cancer
    • Table 125: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs
    • Table 126: Drug Target Profiles of Antibody Drugs for the Treatment of Soft Tissue Sarcoma
    • Table 127: Drug Target Profiles of Antibody Drugs for the Treatment of Solid Tumor
    • Table 128: Drug Target Profiles of Antibody Drugs for the Treatment of Squamous Cell Cancer
    • Table 129: Drug Target Profiles of Antibody Drugs for the Treatment of Synovial Sarcoma
    • Table 130: Drug Target Profiles of Antibody Drugs for the Treatment of T-cell Lymphoma
    • Table 131: Drug Target Profiles of Antibody Drugs for the Treatment of Testicular Cancer
    • Table 132: Drug Target Profiles of Antibody Drugs for the Treatment of Thyroid Cancer
    • Table 133: The Competition through Close Mechanistic Approximation between Thyroid Cancer Drugs
    • Table 134: Drug Target Profiles of Antibody Drugs for the Treatment of Unspecified Cancer Indication
    • Table 135: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs
    • Table 136: Drug Target Profiles of Antibody Drugs as Vaccine Adjunct
    • Table 137: A&G Pharmaceutical's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 138: Abiogen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 139: Ablynx's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 140: AC Immune's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 141: Access' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 142: Actinium Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 143: Active Biotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 144: Adherex's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 145: Affibody's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 146: Affimed Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 147: Affitech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 148: AGY Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 149: Aida Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 150: Alder Biopharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 151: Alethia Biotherapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 152: Alexion's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 153: Algeta's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 154: Amgen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 155: Antisoma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 156: Aphios' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 157: Arana Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 158: Arca biopharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 159: Astellas' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 160: AstraZeneca's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 161: Attenuon's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 162: AVEO's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 163: Bayer's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 164: Berkeley Lab's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 165: Biocon's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 166: Biogen Idec's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 167: BioInvent's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 168: Biolex's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 169: BioLineRx's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 170: Biosceptre's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 171: Biotecnol's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 172: Boehringer Ingelheim's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 173: Bristol-Myers Squibb's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 174: BTG's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 175: Cancer Innovations' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 176: Cancer Research Technology's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 177: Celldex Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 178: Celtic Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 179: Center of Molecular Immunology's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 180: CG Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 181: Circadian Technologies' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 182: CuraGen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 183: CureTech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 184: Curis' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 185: CytImmune Sciences' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 186: Daiichi Sankyo's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 187: Dendreon's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 188: Dompe's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 189: Dyax's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 190: Eisai's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 191: Elan's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 192: Eli Lilly's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 193: Epitomics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 194: EUSA Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 195: Facet Biotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 196: Faron Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 197: Favrille's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 198: FibroGen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 199: Five Prime Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 200: Fusion Antibodies' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 201: Galaxy Biotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 202: GammaCan's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 203: Ganymed Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 204: Gene Techno Science's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 205: Genentech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 206: Genmab's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 207: GenPat77's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 208: Genzyme's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 209: GlaxoSmithKline's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 210: Gliknik's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 211: Glycotope's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 212: Green Cross' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 213: GTC Biotherapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 214: Hoffmann-La Roche's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 215: Human Genome Sciences' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 216: IDM Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 217: ImClone Systems' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 218: ImmunoCellular Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 219: ImmunoGen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 220: Immunomedics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 221: Innate Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 222: InNexus Biotechnology's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 223: Intracel's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 224: ISA Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 225: ISU ABXIS's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 226: Johnson & Johnson's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 227: Kaketsuken's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 228: KaloBios' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 229: Kirin Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 230: Kissei's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 231: Kyowa Hakko Kirin's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 232: LFB Biotechnologies' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 233: MacroGenics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 234: MAT Biopharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 235: Medarex's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 236: MediGene's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 237: MedImmune's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 238: Menarini's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out
    • Table 239: Merck & Co's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1002
    • Table 240: Merck KGaA's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1008
    • Table 241: Merrimack's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1015
    • Table 242: Micromet's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1018
    • Table 243: MorphoSys' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1030
    • Table 244: Neovacs' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1033
    • Table 245: Neuren's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1037
    • Table 246: NKT Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1040
    • Table 247: Non-industrial source's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1043
    • Table 248: Northwest Biotherapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1048
    • Table 249: Novartis' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1051
    • Table 250: OncoMed's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1059
    • Table 251: Onyvax's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1062
    • Table 252: Oxford BioMedica's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1065
    • Table 253: Paladin Labs' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1068
    • Table 254: Panacea's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1073
    • Table 255: PanGenetics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1077
    • Table 256: Patrys' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1081
    • Table 257: Pepscan Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1085
    • Table 258: Peregrine Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1090
    • Table 259: Pfizer's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1095
    • Table 260: Philogen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1105
    • Table 261: Pierre Fabre's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1108
    • Table 262: Prima Biomed's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1114
    • Table 263: ProCell Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1117
    • Table 264: Prochon Biotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1120
    • Table 265: Progenics Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1123
    • Table 266: Protherics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1126
    • Table 267: Ramot's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1129
    • Table 268: Recepta biopharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1132
    • Table 269: Receptor BioLogix's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1135
    • Table 270: Regeneron's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1139
    • Table 271: Sanofi-Aventis' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1144
    • Table 272: Scancell's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1147
    • Table 273: Seattle Genetics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1150
    • Table 274: Sirtex Medical's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1158
    • Table 275: Sunol Molecular's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1162
    • Table 276: SuppreMol's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1165
    • Table 277: Switch Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1168
    • Table 278: Symphogen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1171
    • Table 279: SynerGene Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1176
    • Table 280: Takeda's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1179
    • Table 281: Targa Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1182
    • Table 282: TeGenero's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1187
    • Table 283: Teva's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1190
    • Table 284: Therapure Biopharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1193
    • Table 285: ThromboGenics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1196
    • Table 286: Titan Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1199
    • Table 287: Tolerx's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1204
    • Table 288: Tracon Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1207
    • Table 289: Trillium Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1210
    • Table 290: Trion Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1213
    • Table 291: Trubion's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1218
    • Table 292: UCB's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1221
    • Table 293: United Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1225
    • Table 294: Vaccinex's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1228
    • Table 295: VasGene Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1233
    • Table 296: Viragen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1236
    • Table 297: Viventia Biotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1239
    • Table 298: Wilex's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1242
    • Table 299: Xencor's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1245
    • Table 300: Xerion's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1257
    • Table 301: Xoma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1262
    • Table 302: Y's Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1266